“…Alleviating hypoxia can effectively reduce the level of HIF-1𝛼 to inhibit tumor growth and metastasis, which can be used as an important direction to improve the therapeutic effect of SDT. This requires that the design of sonosensitizers Consumption of GSH LiPTD NPs, HSIPT-NPs, Pt-Cy, HCIr, P-NBOF [181,182,183,184,185] Catalytic CDT FePS3-PEGNSS, ZnO NPs [12,186] Reverse immunosuppression MoOX-PEG [86] GSH-response Reverse immunosuppression H-Pys-HA@M/R, MRP, THPP-Oxa(IV)-PEG [89,187,188] Block the blood flow of cancer 𝛼MM@PLT [92] Consumption of GSH P-DOA NPs [189] Consumption of GSH, Catalytic CDT, pH-response CCC NPs [38] CAT-like activity CSI@Ex-A [190] should aim to not only induce the production of ROS but also effectively promote the production of O 2 in the tumor or carry O 2 .…”